Keros Therapeutics, Inc. financial data

Symbol
KROS on Nasdaq
Industry
Pharmaceutical Preparations
Location
1050 Waltham Street, Suite 302, Lexington, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.92K % -3.15%
Debt-to-equity 8.63 % -9.15%
Return On Equity -41.7 % +8.1%
Return On Assets -38.4 % +7.38%
Operating Margin -31.3K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 40.5M shares +35.2%
Common Stock, Shares, Outstanding 39.3M shares +32.3%
Entity Public Float 905M USD +92.3%
Common Stock, Value, Issued 4K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 37.6M shares +26.7%
Weighted Average Number of Shares Outstanding, Diluted 37.6M shares +26.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 651K USD +4750%
Research and Development Expense 165M USD +34.9%
General and Administrative Expense 39.2M USD +19.4%
Operating Income (Loss) -204M USD -31.3%
Nonoperating Income (Expense) 22.5M USD +73.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -105M USD -84.5%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -182M USD -27.4%
Earnings Per Share, Basic -5.21 USD/shares -5.25%
Earnings Per Share, Diluted -5.21 USD/shares -5.25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 531M USD +84.3%
Accounts Receivable, after Allowance for Credit Loss, Current 388K USD
Other Assets, Current 1.39M USD +334%
Assets, Current 552M USD +81.3%
Property, Plant and Equipment, Net 4.37M USD +30.1%
Operating Lease, Right-of-Use Asset 19.8M USD +26.5%
Other Assets, Noncurrent 1.59M USD +0.83%
Assets 579M USD +77.6%
Accounts Payable, Current 4.98M USD +28.8%
Employee-related Liabilities, Current 8.03M USD +31.3%
Accrued Liabilities, Current 22.2M USD +81.4%
Liabilities, Current 29M USD +73.7%
Operating Lease, Liability, Noncurrent 17.4M USD +27.2%
Liabilities 46.4M USD +52.7%
Retained Earnings (Accumulated Deficit) -523M USD -53.2%
Stockholders' Equity Attributable to Parent 533M USD +80.1%
Liabilities and Equity 579M USD +77.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -44.6M USD -30.2%
Net Cash Provided by (Used in) Financing Activities 157M USD +45.6%
Net Cash Provided by (Used in) Investing Activities -946K USD +10.9%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 39.3M shares +32.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 111M USD +53.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 532M USD +84.1%
Deferred Tax Assets, Valuation Allowance 99.4M USD +63.9%
Deferred Tax Assets, Gross 103M USD +58.9%
Operating Lease, Liability 19.3M USD +34.7%
Depreciation 277K USD +65.9%
Payments to Acquire Property, Plant, and Equipment 946K USD -10.9%
Lessee, Operating Lease, Liability, to be Paid 26.7M USD +23.6%
Property, Plant and Equipment, Gross 5.85M USD +83.9%
Operating Lease, Liability, Current 1.86M USD +204%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4M USD +59.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.8M USD +56.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.42M USD +1.83%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.13M USD +60%
Deferred Tax Assets, Operating Loss Carryforwards 36.2M USD -3.83%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.25M USD +60%
Operating Lease, Payments 500K USD +150%
Additional Paid in Capital 1.06B USD +65.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.66M USD -13.2%
Share-based Payment Arrangement, Expense 33M USD +26%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares